Biology Insights

What Is a Genetic Susceptibility to Breast Cancer?

Learn how an inherited predisposition can influence breast cancer risk and the process for understanding, confirming, and managing that risk with medical guidance.

By Raquel Ortega

Genetic susceptibility to breast cancer means that inherited changes in your DNA raise your chances of developing the disease above the baseline risk in the general population. These changes range from rare, high-impact mutations in genes like BRCA1 and BRCA2 to hundreds of common, individually tiny DNA variations that accumulate into a measurable shift in risk. Roughly five to ten percent of breast cancers are driven primarily by a single inherited gene mutation, but a much larger share of cases involve some degree of inherited predisposition layered on top of lifestyle and environmental exposures.

BRCA1 and BRCA2, the Best-Known Risk Genes

BRCA1 and BRCA2 are tumor suppressor genes. Their job is to help cells repair damaged DNA accurately. When either gene carries a harmful inherited mutation, cells lose a key repair tool, and errors in DNA accumulate faster than they otherwise would. That genomic instability is what eventually pushes cells toward cancer. The link between these genes and breast and ovarian cancer was established over two decades ago, and mutations in both genes have since been connected to elevated risk for several other cancer types as well.

How much do these mutations increase risk? A large prospective study estimated the cumulative breast cancer risk by age 80 at about 72% for BRCA1 carriers and 69% for BRCA2 carriers. A separate meta-analysis looking at risk by age 70 found slightly lower figures, around 57% for BRCA1 and 49% for BRCA2. The variation across studies is real and reflects genuine differences among study populations, family histories, and which specific mutation a person carries. But the broad takeaway is clear: carrying a harmful BRCA1 or BRCA2 mutation puts your lifetime breast cancer risk somewhere in the range of roughly 50% to over 70%, compared with about 13% for the average woman.

Ovarian cancer risk is substantially elevated too. The same prospective study estimated a cumulative ovarian cancer risk to age 80 of about 44% for BRCA1 carriers and 17% for BRCA2 carriers. This dual risk profile for breast and ovarian cancer is a hallmark of BRCA-related susceptibility and shapes how clinicians approach screening and prevention.

Moderate-Risk Genes

BRCA1 and BRCA2 get the most attention, but they are not the only inherited mutations that matter. Several other genes carry mutations that raise breast cancer risk by a moderate amount, typically doubling to quadrupling it rather than pushing it as high as BRCA mutations do. The most prominent of these is PALB2, a gene whose protein works directly with BRCA2 in DNA repair. Two specific PALB2 variants studied in European women showed odds ratios of roughly 3.4 and 4.2 for breast cancer. Variants in ATM and CHEK2, two other DNA-damage-response genes, also showed elevated risk, with one ATM variant carrying an odds ratio of about 11 in that analysis and several CHEK2 variants showing risk roughly one-and-a-half to five times the baseline.

These moderate-risk genes matter clinically because they are more common in the population than BRCA mutations, and because a person who tests negative for BRCA1 and BRCA2 may still carry one of these variants. Current consensus guidelines from the American Society of Breast Surgeons recommend that genetic testing for breast cancer patients include not just BRCA1 and BRCA2 but also PALB2, along with other genes appropriate to the clinical scenario.

Hereditary Syndromes That Include Breast Cancer

Some inherited conditions raise breast cancer risk as part of a broader pattern of cancer susceptibility. Li-Fraumeni syndrome, caused by mutations in the TP53 gene, predisposes people to a wide range of cancers starting at young ages, including breast cancer. Cowden syndrome, linked to PTEN mutations, and several rarer syndromes involving genes like CDH1, STK11, and the mismatch repair genes associated with Lynch syndrome all carry increased breast cancer risk to varying degrees.

These syndromes are individually rare, but they are worth knowing about for two reasons. First, they explain some of the hereditary breast cancer cases that turn up negative on BRCA testing. Second, they may require different surveillance and management strategies because of the additional cancer types involved. In Li-Fraumeni syndrome, for example, reproductive factors like breastfeeding appear to modify breast cancer risk in ways researchers are still characterizing.

Polygenic Risk and the Accumulation of Small Effects

Most of the inherited variation in breast cancer risk does not come from single dramatic mutations. It comes from hundreds or thousands of common genetic variants scattered across the genome, each one nudging risk up or down by a tiny amount. Individually, any one of these variants is almost meaningless. Collectively, they account for a substantial portion of why breast cancer runs in some families. Polygenic risk scores, which add up the effects of these variants into a single number, now explain over 30% of breast cancer’s heritability.

The practical impact of polygenic risk is not trivial. In a large Finnish dataset, a genome-wide polygenic risk score showed a hazard ratio of about 1.71 per standard deviation, meaning that for every standard-deviation increase in your score, your risk rose substantially. Women at the very top and very bottom of the polygenic risk distribution have meaningfully different lifetime risk trajectories, even if no single variant in their genome would be flagged as “pathogenic” on a clinical test.

What makes this more interesting is that polygenic risk also modifies how dangerous a BRCA mutation is. Among BRCA1 carriers, the polygenic score for estrogen-receptor-negative breast cancer showed the strongest association with breast cancer risk, while among BRCA2 carriers, the overall breast cancer polygenic score was more predictive. The combined effects of rare mutations and common variants can create large differences in absolute risk between carriers at opposite ends of the polygenic spectrum. In other words, two people with the same BRCA1 mutation can face quite different risk levels depending on the rest of their genetic background.

How Genes and Lifestyle Interact

A common question after learning about genetic susceptibility is whether lifestyle choices make any difference if your genes already stack the deck. The evidence says yes, they do. In a large UK Biobank study, postmenopausal women who followed a healthy lifestyle saw about a 30% reduction in invasive breast cancer risk regardless of whether they had a low, intermediate, or high polygenic risk score. Among premenopausal women, the greatest benefit of a healthy lifestyle showed up in the highest genetic risk group. The interaction between genetic and lifestyle risk was additive: the benefits of healthy behavior stack on top of whatever baseline risk your genes set, rather than being overwhelmed by it.

Specific gene-lifestyle combinations can amplify risk dramatically. One study found that women who carried certain metabolic-pathway risk variants and were also obese had a roughly five- to seven-fold higher breast cancer risk compared with non-obese women who lacked those variants. Adding daily alcohol consumption on top of obesity and risk-carrying genotypes pushed the risk even higher, suggesting a dose-response pattern where genetic and lifestyle factors compound each other.

Population-Specific Founder Mutations

Certain populations carry specific BRCA mutations at unusually high rates because those mutations arose in a common ancestor and have been passed down through generations. The most well-documented example involves Ashkenazi Jewish populations, where three specific founder mutations in BRCA1 and BRCA2 occur at a combined frequency of about 1 in 40 people. That is roughly ten times the general population’s carrier rate for any BRCA mutation.

An important wrinkle is that many carriers of these founder mutations do not know they have Ashkenazi Jewish ancestry. A study of 23andMe research participants found that about 1 in 46 people with high Ashkenazi Jewish genetic ancestry carried one of the three variants, consistent with prior estimates. But among identified carriers who provided self-reported ancestry, about 21% did not report Jewish heritage at all. This has real implications for screening: relying on self-reported ethnicity alone can miss a significant share of at-risk individuals. The U.S. Preventive Services Task Force recommends that primary care clinicians assess women with ancestry associated with BRCA mutations, among other risk factors, using a brief familial risk assessment tool.

How Genetic Susceptibility Shapes the Type of Cancer

Not all breast cancers are the same, and the specific gene mutation a person carries can influence which subtype of breast cancer is most likely to develop. BRCA1 mutations are strongly linked to triple-negative breast cancer, a subtype that does not respond to hormonal therapies and tends to be more aggressive. A meta-analysis found that BRCA1 mutation carriers were about nine times more likely to develop triple-negative breast cancer than non-carriers, and about three times more likely than BRCA2 carriers. BRCA1-associated tumors also tended to have higher nuclear grades and larger sizes at diagnosis.

BRCA2-associated tumors, by contrast, more frequently resemble the luminal-B subtype, which is hormone-receptor positive and may respond to endocrine therapies. Research comparing the two mutation groups has found that the specific pathogenic variant within each gene may influence which tumor subtype develops, with some variants appearing predominantly in triple-negative cases and others almost exclusively in luminal tumors. This genotype-phenotype connection is one reason that knowing your specific mutation matters for treatment planning, not just risk prediction.

Risk Management for People with High-Risk Mutations

Once a harmful mutation is identified, the menu of risk-management strategies generally falls into three categories: enhanced surveillance, preventive surgery, and medication.

These are deeply personal decisions. They involve trade-offs between cancer risk, quality of life, fertility, and psychological well-being, and they are best made with the support of a genetic counselor and a multidisciplinary medical team.

PARP Inhibitors and the Treatment Angle

Genetic susceptibility is not only about predicting who gets cancer. It also influences how the cancer is treated once it appears. PARP inhibitors are a class of drugs that exploit the same DNA-repair weakness that made the cancer possible in the first place. In cells with functioning BRCA1 or BRCA2 genes, PARP enzymes provide a backup DNA-repair pathway. In cells where BRCA is already broken, blocking PARP removes the last safety net, causing the cancer cell to die. This principle is called synthetic lethality.

PARP inhibitors were the first clinically approved drugs designed around this concept, and they have become a standard part of treatment for BRCA-associated breast and ovarian cancers. This is one of the clearest examples in oncology of how understanding the genetic basis of a cancer directly opens the door to targeted therapy. It also means that genetic testing results carry implications well beyond risk counseling; they can change the treatment a patient receives if cancer develops.

Variants of Uncertain Significance

Genetic testing does not always give a clean answer. Sometimes the lab identifies a variant in a cancer-related gene that has not been seen often enough, or studied well enough, to classify as either harmful or harmless. These results are called variants of uncertain significance, and they can be a source of real anxiety for patients and confusion for clinicians.

The key principle is that a variant of uncertain significance should not be used to make clinical decisions as though it were a confirmed pathogenic mutation. It should not drive someone toward prophylactic surgery. Over time, as more data accumulate, many of these variants are reclassified as benign, and a smaller fraction are upgraded to pathogenic. The challenge is greatest in high-penetrance genes like BRCA1 and BRCA2, where the stakes of misclassification are highest. If you receive a VUS result, a genetic counselor can help you interpret it and develop a follow-up plan that may include periodic reclassification checks.

Limitations of Direct-to-Consumer Genetic Tests

Consumer genetic tests marketed for health purposes have introduced millions of people to the idea of genetic breast cancer risk, but these tests have significant blind spots. The most widely available direct-to-consumer test for hereditary breast and ovarian cancer screens for just three specific BRCA mutations, the Ashkenazi Jewish founder variants. There are more than a thousand known pathogenic BRCA variants. A study comparing direct-to-consumer results with comprehensive clinical testing found that these consumer tests miss over 90% of harmful BRCA1/2 variants in individuals of non-Ashkenazi Jewish ancestry, and still miss about 10% of pathogenic variants even among Ashkenazi Jewish individuals.

A negative result on a direct-to-consumer test does not mean you are in the clear. If you have a strong family history of breast or ovarian cancer, or if other risk factors are present, a clinical-grade multi-gene panel test through a genetics professional is the appropriate next step. The consumer test can be a useful conversation starter, but it is not a substitute for clinical genetic testing.

Legal Protections and the Fear of Discrimination

One reason people hesitate to get genetic testing is the fear that a positive result could be used against them by employers or insurance companies. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from discriminating based on genetic information. Additional protections exist under HIPAA, the Americans with Disabilities Act, and some state laws.

Awareness of these protections is low. A study of young breast cancer survivors found that only about 27% of those who had undergone genetic testing were aware GINA existed, and the figure dropped to 15% among those who had not been tested. An important gap in GINA is that it does not cover life insurance, disability insurance, or long-term care insurance. A Canadian survey found that roughly half of participants believed a breast cancer risk level could affect their ability to buy insurance, and nearly 60% thought insurance could be cancelled if risk information was withheld. These concerns are not irrational, and they are worth discussing with a genetic counselor before testing.

Male Breast Cancer and Genetic Susceptibility

Breast cancer in men is rare, accounting for less than 1% of all breast cancers. But when it does occur, it has a strong genetic component. BRCA1 and BRCA2 mutations account for about 10% of all male breast cancer cases, a much higher proportion than in women, where hereditary mutations explain roughly 5-10% of cases. BRCA2 mutations in particular are associated with a substantially elevated risk of male breast cancer. Among men who test negative for BRCA1 and BRCA2, other genes like PALB2 may be involved; targeted sequencing has identified pathogenic PALB2 variants in BRCA-negative male breast cancer families, supporting the inclusion of PALB2 in clinical testing panels for both sexes.

Emerging Frontiers Beyond the DNA Sequence

The traditional picture of genetic susceptibility focuses on changes in the DNA sequence itself, whether a gene’s code has been altered in a way that disrupts its protein’s function. But researchers are increasingly finding that changes in how genes are regulated, without any alteration to the genetic code, may also contribute to breast cancer risk. DNA methylation, a chemical modification that can silence genes, has shown up as a potential marker. In one study of patients meeting criteria for hereditary breast cancer, abnormal methylation patterns near several cancer-related genes, including PALB2 and the DNA-repair gene FANCI, were associated with increased breast cancer risk.

Changes in noncoding regions of DNA, the vast stretches of the genome that do not directly encode proteins but help control gene activity, are also drawing attention. These noncoding variants and epigenetic alterations could help explain some of the inherited risk that current gene panels and polygenic scores do not capture. This is still early-stage research, but it points toward a future where genetic susceptibility assessment goes beyond reading the sequence of known cancer genes and starts incorporating how those genes are turned on and off.

Related Content

More in Cancer